Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Resource
  2. Source: Campus Sanofi
  3. 19 Sept 2025

Expert Insights on Advancing the Conversation on Disease Modification in Atopic Dermatitis

Author: Sanofi

Campus Sanofi

Dupixent (dupilumab) Prescribing Information UK

Explore our Expert Encounter series focused on Atopic Dermatitis. Uncover new strategies for managing comorbidities, learn about the latest evidence supporting disease-modifying therapies, and gain practical guidance for implementing these approaches in your clinical practice.

Exploring Disease Modification in Atopic Dermatitis: Insights from International Experts

In this enlightening Q&A session, dermatology experts Professor Cork and Professor Thaçi share their valuable insights on the evolving landscape of Atopic Dermatitis treatment, with a focus on disease modification.

These videos offer valuable perspectives for Dermatologists and healthcare professionals seeking to optimise their approach to managing atopic dermatitis, particularly in cases where traditional treatments have not provided adequate control.

The Paradigm Shift in Atopic Dermatitis Management: From Control to Disease Modification

A Sanofi sponsored symposium presented at the British Association of Dermatologists Annual Meeting, July 2025

This symposium, chaired by Dr. Andrew Pink, featured insights from Professor Michael Ardern-Jones and Professor Diamant Thaçi on the evolving landscape of atopic dermatitis (AD) management. The experts discussed the transition from symptom control to disease modification in AD treatment.

Key topics included strategies for managing AD comorbidities, with a focus on ocular complications, and the latest evidence supporting the disease modification potential of targeted therapies. The faculty presented the latest data on sustained clinical control, barrier restoration, and the impact of treatment on growth, microbiome normalisation, and nerve fibre density in AD patients.

The symposium highlighted the importance of early intervention to potentially reduce cumulative life course impairment in AD. Practical guidance was provided for implementing disease-modifying therapies in clinical practice, including monitoring and managing treatment-related effects.

This paradigm shift in AD management emphasises long-term strategies for moderate-to-severe cases, aiming to alter the disease course beyond symptom control. The full recording offers in-depth discussions on these critical developments in AD care.

Discover other resources  

Photo of the paper ADCT test

Atopic Dermatitis Control Test (ADCT)

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

Try the ADCT

MAT-XU-2503952 (v1.0) Date of preparation: September 2025